Global Therapeutic BCG Vaccines Market Size and Forecast 2024-2033 | Merck & Co Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd.

The Therapeutic BCG Vaccines  by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Therapeutic BCG Vaccines  Market:

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

According to The Business Research Company’s Therapeutic BCG Vaccines , The therapeutic bcg vaccines market size has grown strongly in recent years. It will grow from $53.99 billion in 2023 to $57.14 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%.  The  growth in the historic period can be attributed to government initiatives for tb control, immune system modulation, global immunization programs, treatment of bladder cancer, investments in vaccine manufacturing, emergence of drug-resistant tb strains..

The therapeutic bcg vaccines market size is expected to see strong growth in the next few years. It will grow to $72.54 billion in 2028 at a compound annual growth rate (CAGR) of 6.1%.  The growth in the forecast period can be attributed to expansion to other indications, increased research on immunotherapy, global efforts against emerging infectious diseases, regulatory support for vaccine development, focus on tuberculosis elimination.. Major trends in the forecast period include advancements in vaccine technology, supply chain optimization, market consolidation and partnerships, patient education and awareness, alternative delivery methods, personalized medicine approaches..

The rising number of tuberculosis (TB) cases worldwide will propel the growth of the therapeutic BCG vaccine market going forward. Tuberculosis (TB) is an infectious illness that can be potentially dangerous and primarily impacts the lungs. People can contract tuberculosis from one another by coughing or sneezing small droplets of bacteria into the air. BCG vaccines are used to stimulate the immune system to fight infection but do not cause TB since the germs are weak. It consistently offers protection against the most dangerous types of TB, such as adolescent TB meningitis. The BCG vaccine protects against tuberculosis which helps to fight against infection, hence the usage of therapeutic BCG vaccines increased. For instance, in October 2022, according to a report published by the World Health Organization, a specialized agency of the United Nations responsible for international public health, 10.6 million people were predicted to have contracted tuberculosis (TB) in 2021, an increase of 4.5% from 2020, and 1.6 million died from TB (including 187,000 HIV-positive individuals). Therefore, the rising number of tuberculosis (TB) cases worldwide is driving the growth of the therapeutic BCG vaccine market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=9178&type=smp

The therapeutic bcg vaccines market covered in this report is segmented –

1) By Type: Therapy BCG, Immune BCG
2) By Demographics: Pediatrics, Adults
3) By End Use: Hospitals, Clinics, Other End Users

Strategic partnerships have emerged as a key trend gaining popularity in the therapeutic BCG vaccine market. Major companies operating in the therapeutic BCG vaccine market are focused on collaborating with other key players to sustain their position in the market. For instance, in July 2021, Zendal, a Spain-based pharmaceutical company, partnered with IAVI,  a US-based not-for-profit organization to advance the tuberculosis vaccine candidate MTBVAC into efficacy trials. The only live, attenuated Mycobacterium tuberculosis vaccine currently being developed is MTBVAC. It is now being developed to prevent tuberculosis in adults and adolescents, for whom there is currently no effective vaccination, and as a more potent and potentially long-lasting vaccine than BCG for infants. This statement coincides with the rapid development of several vaccinations to guard against COVID-19.

The therapeutic bcg vaccines  market report table of contents includes:

1. Executive Summary

2. Therapeutic BCG Vaccines Market Characteristics

3. Therapeutic BCG Vaccines Market Trends And Strategies

4. Therapeutic BCG Vaccines Market – Macro Economic Scenario

…

31. Global Therapeutic BCG Vaccines Market Competitive Benchmarking

32. Global Therapeutic BCG Vaccines Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Therapeutic BCG Vaccines Market

34. Therapeutic BCG Vaccines Market Future Outlook and Potential Analysis

 

 

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model